Severe haemophilia A with haemarthrosis improved on emicizumab: A case report
Mustafa Wasifuddin
Orcid-Profil und Ibrahim Al-Gaithi
Orcid-Profil 
Artikel-Kategorie: Case Study
Online veröffentlicht: 19. März 2025
Seitenbereich: 29 - 33
DOI: https://doi.org/10.2478/jhp-2025-0004
Schlüsselwörter
© 2025 Mustafa Wasifuddin et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Introduction
Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes in adults and children with haemophilia A with or without inhibitors.
Case presentation
In this case report, we discuss the case of a 10-year-old child with severe haemophilia A without inhibitors. He was initially managed with on-demand and prophylactic plasma-derived factor VIII and, after complications due to haemarthrosis, emicizumab. Treatment with emicizumab was associated with improved quality of life.
Conclusion
This case report shows that disease-related complications, particularly haemarthrosis, and health-related quality of life can be improved after the initiation of emicizumab.